- Home
- XBIT vs TIL Comparison
XBIT vs TIL Comparison
Compare XBIT & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XBIT | TIL |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.2M | 74.7M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XBIT | TIL |
|---|---|---|
| Price | $2.39 | $7.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | 46.3K | ★ 263.2K |
| Earning Date | 03-17-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.09 | $5.67 |
| 52 Week High | $3.62 | $42.79 |
Technical Indicators
Market Signals| Indicator | XBIT | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 38.90 | 34.43 |
| Support Level | $2.49 | $6.79 |
| Resistance Level | $2.66 | $7.44 |
| Average True Range (ATR) | 0.11 | 0.28 |
| MACD | -0.03 | 0.18 |
| Stochastic Oscillator | 18.91 | 50.56 |
Price Performance
Historical ComparisonAbout XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.